share_log

Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target

Moomoo 24/7 ·  Apr 23 13:14

Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment